Schizophrenia Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Schizophrenia Drugs Market Forecast and it is Segmented by Therapeutic Class (Second-generation Antipsychotics, Third-generation Antipsychotics, and Other Therapeutic Classes), Treatment (Oral and Injectables), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market values are provided in terms of (USD billion) for the above segments.

Schizophrenia Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Schizophrenia Drugs Industry Overview

The schizophrenia drugs market is highly competitive and consists of major and small players. In terms of market share, major players currently dominate the market. Some of the major market players include Alkermes PLC, Otsuka Pharmaceuticals, Eli Lilly and Company, Johnson & Johnson, and AbbVie (Allergan PLC), among others.

Schizophrenia Drugs Market Leaders

  1. Johnson & Johnson

  2. Eli Lilly and Company

  3. AbbVie Inc.(Allergan Plc)

  4. Alkermes PLC

  5. Otsuka Pharmaceutical Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Schizophrenia Drugs Market Concentration

Schizophrenia Drug Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?